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Abstract
Background: Colorectal cancer (CRC) is the third most common cancer worldwide. If detected at an early stage,
prognosis is good. Despite increasing evidence for the benefits of implemented screening programs, such as
screening colonoscopy, compliance is rather low. Hence there is demand for non-invasive tests for the early detection
of CRC with high acceptance in population-wide screening. The objective of this study was to identify and evaluate
leukocyte DNA methylation patterns as a potential biomarker for early detection of CRC.
Methods: Blood samples of patients scheduled for a screening colonoscopy were collected before the procedure.
Additionally, blood samples from CRC cases recruited in a clinical setting were collected. DNA was extracted from
leukocytes, and DNA methylation was measured with the Infinium 450K BeadChip. In total, 46 CRC cases and 140
controls from the screening setting and 93 CRC cases from the clinical setting were measured.
Results: An epigenome-wide discovery revealed two CpG sites in the promoter region of KIAA1549L that were
significantly differentially methylated between cases and controls. A third marker in the body region of BCL2 was
discovered in a candidate approach testing biomarkers reported in the literature. Logistic regression models built on
these three markers yielded an optimism-corrected c-statistic of 0.69 in the screening setting and 0.73 in the clinical
setting.
Conclusions: Although diagnostic performance of the DNA methylation signature identified in this first epigenome-
wide association study of leukocyte DNA methylation with CRC in a screening setting is not competitive with
established screening tests, the identified markers may contribute to multimarker panels for early detection of CRC.
Keywords: Biomarker, Colorectal cancer, Early detection, Screening setting, DNA methylation, Illumina Infinium 450K,
Epigenome-wide association study, EWAS, Leukocyte composition
Background
With ∼1.4 million incident cases and almost 700,000
deaths in 2012, colorectal cancer (CRC) is the third most
common cancer and the fourth most common cause of
cancer death worldwide [1]. Stage at diagnosis is the
most important prognostic factor with relative 5-year
survival rates of 90, 74, and 14% when diagnosed at a
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localized, regional, and advanced stage, respectively [2].
Colonoscopy is the gold standard for the detection of CRC
and its precursors. CRC is diagnosed earlier by screening
colonoscopy [3] and can even be prevented by removing
precursors during colonoscopy. In a recent meta-analysis,
screening colonoscopy was estimated to reduce the risk of
incident CRC by 69% and CRC mortality by 68% [4].
In Germany, a first screening colonoscopy is offered free
of charge to men and women aged 55 and older, a sec-
ond one is possible after 10 years. Alternatively, biennial
fecal occult blood tests can be performed. Nearly 90% of
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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the people entitled were found to be aware of this pro-
gram [5], but despite awareness and clear benefits, less
than 40% were up to date with CRC screening recom-
mendations [6]. A recent study among 172 asymptomatic
participants recruited during regular consultations found
that 109 (63%) refused to undergo screening colonoscopy,
but of these, 106 (97%) accepted non-invasive screening
methods with 90 (83%) choosing a blood-based test [7].
Although blood tests do not achieve the excellent perfor-
mance of colonoscopy or immunochemical fecal occult
blood tests, their value comes from the high acceptance
by patients. Higher participation in screening programs
could lower CRC mortality.
Only a fraction of the biomarkers for the early detec-
tion of cancer reported in the literature find their way
to clinical application eventually. Promising results from
retrospective case-control studies often cannot be vali-
dated in prospective studies. A great number of blood-
based biomarkers for the early detection of CRC have
been reported [8], but only one has been approved by
the U.S. Food and Drug Administration so far: the Epi
proColon test (Epigenomics AG, Berlin, Germany), that
measures themethylation of the SEPT9 gene in circulating
cell-free DNA in blood, detected CRC with a sensitivity
(specificity) of 48% (92%) in a screening setting [9]. Sev-
eral studies have reported leukocyte DNA methylation
(DNAm) markers for various types of cancer (Additional
file 1: Table S1), but none of these studies were conducted
in a screening setting.We used blood samples fromBLITZ
(German: Begleitende Evaluierung innovativer Testver-
fahren zur Darmkrebs-Früherkennung), a study among
participants of screening colonoscopy, to conduct the
first epigenome-wide association study (EWAS) for leuko-




We analyzed blood samples collected in a screening set-
ting (BLITZ study) and in a clinical setting (DACHS+
study). Details of both studies have been described else-
where [10, 11]. In brief: BLITZ is conducted in coopera-
tion with several gastroenterological practices in Southern
Germany. Eligible are men and women aged 55 to 75
who are scheduled for a screening colonoscopy. They are
informed about the study and invited to participate by
their physicians at a preparatory visit for the colonoscopy.
Participants are excluded, if colonoscopy is indicated due
to other reasons (e.g., visible rectal bleeding or a posi-
tive test for fecal occult blood), if they had a previous
endoscopic examination within the preceding 5 years, or
if they had a previous gastrointestinal cancer diagnosis.
Blood samples are taken before the colonoscopy; after-
wards, medical reports are obtained from the physicians.
Recruitment is ongoing; 6613 participants had been
enrolled by the end of 2014. They were classified accord-
ing to themost advanced findings as follows: CRC (n = 57),
advanced adenomas, non-advanced adenomas, undefined
polyps or other findings of the colonic mucosa (such as
pseudopolyps), hyperplastic polyps (n = 643), neither of
these findings (n = 3856). For this analysis, we selected
CRC cases and participants of the last two categories as
controls; all other categories were excluded.
Because of the limited number of CRC cases even in
such a large screening study, CRC cases recruited in a
clinical setting in the DACHS+ study were included in
addition. In the DACHS+ study, 819men and women aged
55 to 75 with a first diagnosis of a gastrointestinal cancer
between October 2006 and December 2014 from several
clinics in SouthWest Germany were recruited. Patients
with a previous cancer diagnosis in the gastrointestinal
tract were excluded. Blood samples were collected before
surgery.
Sample selection and processing
For the current analysis, blood samples from 47 CRC cases
and 141 controls from BLITZ and 94 CRC cases from
DACHS+ were used. An overview of the selection proce-
dure is depicted in Fig. 1. DNA was extracted from buffy
coat samples and DNA methylation was measured on
the Infinium HumanMethylation450 BeadChip (Illumina,
San Diego, CA, USA) (450K) at the Genomics and Pro-
teomics Core Facility at the German Cancer Research
Center, Heidelberg, Germany, according to the manufac-
turer’s instructions. This platform queries the methylation
levels of 485,512 CpG sites. To minimize potential impact
of batch effects, samples were allocated to three 96-well
plates as follows: plate Awith randomly selected screening
CRC cases and controls from BLITZ 1:1-matched for sex
and age; plate B with randomly selected clinical CRC cases
from DACHS+ and controls from BLITZ 1:1-matched for
sex and age; and plate C as plate B. We will refer to the
samples on plate A as screening setting and to the samples
on plates B and C as clinical setting.
Epigenome-wide marker discovery
450K data were normalized using the R package normal-
ize450K [12]. Methylation levels of each CpG site were
regressed linearly on disease status and the following
covariates: sex, age, leukocyte composition, and batch (96-
well plate on which samples were run). Methylation levels
were expressed as β-values because of their linear rela-
tion with cell proportions. Cell proportions of six major
leukocyte types were estimated according to Houseman
et al. [13], including granulocytes, monocytes, CD8+ T-
cells, CD4+T-cells, natural killer cells, and B lymphocytes.
Disease status was coded by two variables, screening and
clinical, in such a way that screening cases and clinical
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Fig. 1 Sample selection. Blood samples from CRC cases and controls free of colorectal neoplasms collected in a screening setting (BLITZ) and from
CRC cases collected in a clinical setting (DACHS+) were used. A selection of samples matched for sex and age were measured on the Illumina
Infinium 450K chip. The final numbers of samples used for the current analysis, after the exclusion of three samples with unreliable measurements
(QC, quality control), are indicated at the bottom
cases were compared only to controls within the same
setting. We compared this first model to a second one
without screening and clinical and used the likelihood-
ratio test to assess their significance. CpG sites that were
significantly associated at a false discovery rate of 10% and
showed a consistent trend in the screening and clinical
setting (same sign for regression coefficients rs and rc of
screening and clinical) were selected as markers.
Literature search
In addition to the hypothesis-free approach, we also
deployed a targeted approach. We searched PubMed for
publications from January 2011 to June 2016 reporting
leukocyte DNAm markers for any kind of solid can-
cer. We found 18 relevant publications which reported
either probe identifier (in case they used the 27K or 450K
platform) or genes, in which case they were mapped to
probes on the 450K chip using the annotation provided
by the manufacturer. Five publications reported 14 probe
identifiers and 13 publications reported 32 genes mapping
to 733 probes. Association of these in total 747 probes
with CRC was tested using the same approach as in the
epigenome-wide discovery. Search terms and a list of all
included publications are provided in Additional file 1:
Table S1.
Fitting diagnostic models
β-values of the markers discovered in the previous steps
were adjusted for leukocyte composition and batch effects
by subtracting related terms from the corresponding lin-
ear regression models to compute β ′. Three different
models for CRC diagnosis were trained by logistic regres-
sion: (i) a risk-factors-only model that included only the
risk factors sex and age; (ii) a markers-only model that
included only β ′-values of the epigenetic markers; and
(iii) a full model, including both markers and risk factors.
To avoid overoptimism and to provide 95% confidence
intervals, we generated 1000 stratified bootstrap samples
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(“stratified” meaning, that the number of cases and con-
trols was the same as in the original sample). Models were
fitted on the bootstrap samples and tested on the left-out
subjects. This was done separately for the screening set-
ting (plate A) and the clinical setting (plates B and C).
Discrimination was measured by the c-statistic.
Estimating model performance in the BLITZ population
The improvement in discrimination in the matched
case-control sample by the full model compared to
the risk-factors-only model does not represent the
improvement in discrimination in the BLITZ popula-
tion. Matching eliminated the association between CRC
and the risk factors sex and age. We used the approach
described in [14] to correct and weight the scores
from our logistic regression models. Let Yi be the out-
come (case/control), Xi the biomarker levels, and Zi
the other risk factors for subject i. To correct the log
odds lnO(Yi|Xi,Zi)M from the logistic regression model
trained on the matched case-control sample M, sub-
tract lnO(Yi|Zi)M, the log odds from the risk-factors-
only model, and add lnO(Yi|Zi), the log odds from
the risk-factors-only model trained on the entire BLITZ
population.
lnO(Yi|Xi,Zi)′ = lnO(Yi|Xi,Zi)M − lnO(Yi|Zi)M
+ lnO(Yi|Zi)
The result should now reflect the impact of the risk
factors. To account for the different distribution of Z in
the population than in the matched sample, subjects were
weighted by inverse propensity scores (a logistic regres-
sion with the dependent variable indicating if a subject
is included in the matched sample and Z as predictors),
so that the weighted matched sample reflected the dis-
tribution of Z in the BLITZ population. Discrimination
was measured by the weighted c-statistic. Performance of
the other models in the BLITZ population was estimated
analogously.
Results
Three 450K assays failed the quality control (one case
from each setting and one control). Study population
characteristics of the remaining participants are presented
in Table 1. The same table also lists the estimated aver-
age leukocyte proportions among screening cases, clinical
cases, and controls. Differences in cell proportions were
larger between clinical cases and controls than between
screening cases and controls for all cell types. This shows
that leukocyte composition is indeed an important poten-
tial confounder, even more so in the clinical setting.
At a false discovery rate of 10%, there was a single
significant hit (without adjustment for LC, there would
have been 90,288), cg04036920, located 1373 basepairs
upstream to the transcription start site of KIAA1549L.
Methylation levels of proximal CpG sites are often cor-
related; therefore, we tested the remaining 25 probes on
the 450K chip that are ascribed to KIAA1549L, in case
we missed some of them due to the high multiple-testing
burden. After Bonferroni correction (significance level
α < 0.05/25), one other site was significant, cg14472551,
which is located 557 basepairs apart from cg04036920
and 817 basepairs upstream to the transcription start
site. Cases showed higher methylation levels than con-
trols consistent between screening and clinical setting
for both markers (cg04036920 rs = 0.029, rc = 0.032;
cg14472551 rs = 0.042, rc = 0.022). Two more probes
were significant at a false discovery rate of 10% when we
tested only the candidates extracted from our literature
search (without adjustment for LC there would have been
170). One was excluded, as rs and rc showed opposite
trends. The other probe, cg12459502 (rs = 0.011, rc =
0.025), located in the body region of BCL2, was added
to the marker panel. Based on nine technical replicates
of a single sample, allocated on the same plates, we
estimated standard measurement errors of 0.029, 0.019,
and 0.019 for cg04036920, cg14472551, and cg12459502,
respectively.
Thirty-three cases from DACHS+ received neoadjuvant
therapy before blood sampling. In a sensitivity analysis,
we excluded these cases (but kept the matched controls).
While cg04036920 was no longer significant after correc-
tion for multiple testing in the epigenome-wide search, it
remained the marker with the smallest p-value. The tar-
geted search yielded again cg12459502, this time as the
only significant marker.
All three markers were associated with leukocyte com-
position, meaning that some of the regression coefficients
assigned to cell proportions were highly significant. How-
ever, due to the nature of compositional data, variabil-
ity in whole blood DNAm levels cannot be assigned to
individual cell types. Additional file 1: Figure S1 shows
the methylation levels of these markers in seven puri-
fied leukocyte types. Table 2 shows the single marker
performance after adjusting β-values for leukocyte com-
position and batch effects. ROC curves are provided in
Figs. 2 and 3.
Diagnostic models based on these three markers and
the risk factors sex and age were trained and evaluated
via bootstrapping. Table 3 shows the results separately
for the screening setting and the clinical setting. c-
statistics of the risk-factors-only models were around 0.5,
as matching eliminated the association of sex and age with
CRC. The risk-factors-only models reached c-statistics
of 0.68 and 0.74 after weighting the matched samples
for the screening setting and clinical setting, respectively.
The full models did not perform better than the markers-
only models in the matched samples, as expected, but also
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Table 1 Study population characteristics
Cases Controls
BLITZ population
Sex (m/f) 38/19 1,978/2,521
Mean age ± SD 67 ± 7 62 ± 7
Smoking (never/ever) 25/32 2,313/2,175/11a
Stage (Tis/I/II/III/IV) 4/19/6/19/3/6a —
Screening setting (plate A)
Study BLITZ BLITZ
Sex (m/f) 30/16 29/17
Mean age ± SD 67 ± 7 67 ± 7
Smoking (never/ever) 21/25 25/21
Stage (Tis/I/II/III/IV) 2/15/5/16/3/6a —
Cell proportions ||
Granulocytes 54.9 ± 12.8 48.7 ± 14.9 6.2
Monocytes 7.2 ± 1.9 7.6 ± 2.8 0.4
Natural killer cells 11.7 ± 5.2 13.3 ± 5.8 1.7
CD8+ T cells 3.5 ± 4.1 4.4 ± 3.8 0.9
CD4+ T cells 16.7 ± 7.7 19.1 ± 9.5 2.3
B lymphocytes 5.9 ± 2.8 6.8 ± 3.9 0.9
(Difference in mean LC is not significant, p-value 0.29)c
Clinical setting (plates B and C)
Study DACHS+ BLITZ
Sex (m/f) 57/36 57/37
Mean age ± SD 65 ± 8 65 ± 8
Smoking (never/ever) 43/50 47/47
Stage (Tis/I/II/III/IV) 4/28/41/29/22/1a —
Neoadj. therapy (none/rad./chemo./comb.)b 60/12/2/19 —
Cell proportions ||
Granulocytes 64.9 ± 12.8 52.3 ± 12.6 12.6
Monocytes 9.3 ± 3.8 7.8 ± 2.7 1.5
Natural killer cells 7.2 ± 4.3 11.1 ± 5.2 3.9
CD8+ T cells 2.0 ± 2.9 3.5 ± 3.9 1.5
CD4+ T cells 12.6 ± 7.1 19.4 ± 7.8 6.9
B lymphocytes 4.0 ± 2.6 5.9 ± 2.9 1.9
(Difference in mean LC is significant, p-value 3.9 × 10−11)c
Study population characteristics stratified by plate. Subjects who smoked regularly more than 1 year of their life were defined as ever smokers. || gives the absolute
difference in average leukocyte proportions between cases and controls
aMissing values
bNeoadjuvant therapy (none/radiation/chemotherapy/combination of radiation and chemotherapy)
cAs cell proportions are compositional data, differences between cases and controls should not be tested for individual cell types, but for the composition as a whole. The
isometric log-ratio transformation was applied and differences were tested using multivariate analysis of variance (MANOVA) as described in [25]
in the population setting did the combination of markers
and risk factors barely improve discrimination compared
to the markers-only models. Respective c-statistics in the
clinical setting were all higher, going up to 0.81 for the
full model.
Discussion
We analyzed blood samples of CRC cases and controls
collected prospectively from participants of screening
colonoscopy. Additionally, blood samples from clinical
CRC cases were collected. An epigenome-wide discovery
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Table 2 Single marker performance in matched case-control
sample




Discrimination of CRC cases and controls by single markers measured by the
c-statistic in the screening and clinical setting. Methylation levels were adjusted for
leukocyte composition and batch effects
of leukocyte DNAm markers for the early detection of
CRC identified two differentially methylated CpG sites
located near the transcription start site of KIAA1549L. A
third marker in the body region of BCL2 was identified
in a targeted approach looking only at candidate markers
reported in the literature. Discrimination (measured by
the c-statistic) of CRC cases and controls by logistic
regression models based on these three markers was 0.69
and 0.73 in the screening setting and clinical setting,
respectively, and was estimated at 0.74 for the target pop-
ulation of the German CRC screening program. To our
knowledge, this is the first epigenome-wide association
study (EWAS) for leukocyte DNAm markers for the early
detection of CRC in a screening setting.
Screening colonoscopy, the gold standard for the detec-
tion of CRC and precursors, suffers from low adherence.
Non-invasive tests could increase participation in CRC
screening programs and interest in the identification of
























Fig. 2 Single marker performance in screening setting. ROC curves of
the three markers after correction of β-values for leukocyte
























Fig. 3 Single marker performance in clinical setting. ROC curves of the
three markers after correction of β-values for leukocyte composition
and batch effects
validated in a screening setting: the most advanced blood
test so far, based on the detection of cell-free methylated
SEPT9 in plasma, achieved a sensitivity (specificity) of
48% (92%) for the detection of CRC [9]. The combination
of two other markers, CEA and anti-TP53 antibody, also
evaluated in the BLITZ study (albeit not using the same
samples as in the current analysis), achieved a sensitivity
(specificity) of 58% (90%) [15].
Stool tests represent another non-invasive alternative.
The Cologuard test (Exact Sciences, Madison, WI, USA)
combines assays to test for aberrant methylation of the
Table 3 Performance of diagnostic models
Model Matched sample BLITZ population
Screening setting
Risk-factors-only model 0.43 (0.29,0.55) 0.68 (0.57,0.76)
Markers-only model 0.69 (0.55,0.82) 0.74 (0.57,0.87)
Full model 0.69 (0.54,0.83) 0.76 (0.61,0.87)
Clinical setting
Risk-factors-only model 0.45 (0.35,0.54) 0.74 (0.70,0.77)
Markers-only model 0.73 (0.63,0.83) 0.78 (0.66,0.88)
Full model 0.73 (0.61,0.82) 0.81 (0.71,0.88)
Mean and 95% confidence intervals of c-statistics. Values for “BLITZ population”
represent a weighting of participants from the matched sample to achieve similar
distribution of risk factors as in the BLITZ population. The three models are: (i)
risk-factors-only model including sex and age; (ii) markers-only model, including
methylation levels of the three identified biomarkers; and (iii) full model, combining
both risk factors and markers
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promoter regions of the BMP3 and NDRG4 genes, for
mutations of the KRAS gene, and for human hemoglobin.
A score calculated from the combined results from these
assays led to an improved sensitivity (but decreased speci-
ficity) of 92% (87%) compared to 72% (95%) when using
only the hemoglobin component [16]. In the BLITZ study,
a standalone fecal immunochemical occult blood test
(FIT) had a sensitivity (specificity) of 73% (96%) [17]. FITs
perform so far substantially better than blood-based tests.
Our study has several strengths and limitations. Most
importantly, we are using CRC cases and controls from
a true screening setting. Blood samples in BLITZ were
collected before the participants were aware of their
case/control status, thereby eliminating (largely) the pos-
sibility of selection bias and information bias. Case-
control studies using clinical settings often try to account
for selection bias by matching cases and controls on
a number of confounders. However, there might be
unknown confounders which cannot be accounted for and
which might result in false positive candidate markers.
Using a screening setting ensures that cases and controls
are (on expectation) comparable even for the unknown
confounders. For instance, Prolactin, discovered in a clin-
ical setting as a biomarker for ovarian cancer, failed in a
screening setting later and turned out to be sensitive to
the way samples were collected (at the day of a planned
surgery or in the days before) and might just be a symp-
tom of stress [18, 19]. There might be many ways in which
patients change their lifestyle after a cancer diagnosis. In
such cases, not the presence of the disease but being aware
of it might cause differences in biomarker levels. Using
a screening setting avoids these pitfalls. Of course, these
considerations do not apply to the DACHS+ study. There-
fore, we filtered out candidates that showed a inconsistent
trend in the screening and clinical setting. Furthermore,
the BLITZ population closely resembles the target pop-
ulation, as should the AUC estimates of the diagnostic
models.
Another strength of our study is the high sample size.
BLITZ is one of the largest screening studies for CRC with
more than 6600 participants. Therefore, despite the low
prevalence of CRC in the BLITZ population (<1%), we
had approximately 60 samples of CRC to choose from.We
still might have missed potential markers due to a lack of
statistical power caused by the high multiple testing bur-
den. We compensated for this by including samples from
clinical CRC cases, but, as outlined above, they are no
equivalent substitute.
We matched cases and controls on the risk factors sex
and age. Matching would not be necessary in BLITZ, as
the study population closely mirrors the target popula-
tion, in which these groups differ on these factors, and
might even lead to biased estimates of sensitivity and
specificity if marker levels are associated with the factors
matched on [20, 21]. Matching was done here to increase
the statistical power to find biomarkers that provide diag-
nostic value beyond these known risk factors. We used
the method described in [14] to arrive at presumably
unbiased estimates of marker performance in the BLITZ
population.
Another strength of our study is the adjustment for
leukocyte composition (LC). LC is often considered as
the most important confounder when analyzing whole
blood DNAm [22]. This turned out to be true here as
well. Clinical cases and controls differed much more
than screening cases and controls, which may reflect the
higher fraction of late stages among clinical cases and
the fact that some received neoadjuvant therapy. Con-
founding by LC might be one of the reasons, why none
save one candidate marker from our literature search
could be validated here. Only two of the studies included
did adjust for LC, and none was conducted in a screen-
ing setting (with the exception of one study looking at
colorectal adenomas). Indeed, an unadjusted analysis of
our data would have confirmed 170 of the 747 markers.
Another reason might be that those markers are spe-
cific for the types of cancer investigated in the original
studies.
We adjusted for six major leukocyte types, yet we can-
not exclude the possibility that observed differences at
the identified markers are still due to residual confound-
ing, either due inaccurate cell proportion estimates or
because an even finer distinction of cell types would be
necessary. On the other hand, regardless if the observed
effects represent genuine changes of the methylation
state or not, a biomarker must merely hold predictive
value. One could use not only the marker panel but also
harness the predictive value of the leukocyte composi-
tion, as proposed in [23]. Again, as seen in the differ-
ences in leukocyte composition between screening and
clinical cases, such markers would need to be evalu-
ated in a screening setting. A detailed investigation of
this issue was beyond the scope of this work. However,
metrics like the neutrophil/lymphocyte ratio are influ-
enced by many factors and therefore cannot be specific
for CRC.
It is unlikely that observed differences between cases
and controls are caused by batch effects. Blood sam-
ples were collected blinded to the outcome, as well were
DNA extraction and DNAmmeasurements. Batch effects
are omnipresent and numerous for the 450K platform
[24], but our careful sample allocation scheme ensured
that they were not associated with the outcome or the
matching factors.
It is unclear if the identified methylation signature is
specific for CRC, as in contrast to cell-free DNA in blood
serum which might originate from tumor tissue, changes
in leukocyte DNAmethylation probably reflect a response
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of the immune system which might be similar for other
cancers or diseases.
The function of KIAA1945L is largely uncharacterized;
therefore, we refrain from speculations about the biologi-
cal plausibility of this finding.
Conclusions
We identified three CpG sites whose methylation levels
in whole blood can be used as biomarkers for the early
detection of colorectal cancer. While their performance
on their own is not competitive to screening colonoscopy
or fecal immunochemical tests, their combination in a
multi-marker panel, similar to the multitarget stool test
mentioned above [16], could render them useful as a
screening tool. Further validation of these markers in
other study populations is necessary.
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